Nov 14, 2024 · We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related …

4 days ago · Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

4 days ago · Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

6 days ago · Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out …

5 days ago · Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the …

We have developed a platform prodrug technology that adds a small linker to a known or novel kinase inhibitor and suppresses on-dosing side effects common to drugs in this class, …

Oct 21, 2024 · Inhibikase's multi-therapeutic pipeline includes its neurodegenerative disease portfolio led by risvodetinib in Parkinson’s disease, Multiple System Atrophy and other …

Jan 25, 2023 · After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic. The FDA unexpectedly placed a clinical hold on the midstage …

Mar 8, 2023 · Inhibikase is inhibited no longer, nabbing another go-ahead from regulators to enter the clinic with its sole neurodegeneration asset to treat patients with a rare brain disease.

Oct 5, 2023 · The US Food and Drug Administration (FDA) has granted Inhibikase Therapeutics’ risvodetinib orphan drug designation, speeding up a potential therapy for multiple system …